Dimensional Fund Advisors LP Has $443,000 Position in Atara Biotherapeutics Inc (ATRA)

Dimensional Fund Advisors LP cut its stake in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 45.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,053 shares of the biotechnology company’s stock after selling 9,918 shares during the period. Dimensional Fund Advisors LP’s holdings in Atara Biotherapeutics were worth $443,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. State of Wisconsin Investment Board grew its stake in shares of Atara Biotherapeutics by 53.9% during the second quarter. State of Wisconsin Investment Board now owns 41,400 shares of the biotechnology company’s stock worth $1,521,000 after purchasing an additional 14,500 shares during the period. Rhumbline Advisers grew its stake in shares of Atara Biotherapeutics by 16.9% during the second quarter. Rhumbline Advisers now owns 39,238 shares of the biotechnology company’s stock worth $1,442,000 after purchasing an additional 5,673 shares during the period. Highland Private Wealth Management acquired a new stake in shares of Atara Biotherapeutics during the second quarter worth $202,000. Principal Financial Group Inc. acquired a new stake in shares of Atara Biotherapeutics during the first quarter worth $214,000. Finally, California Public Employees Retirement System acquired a new stake in shares of Atara Biotherapeutics during the first quarter worth $2,203,000.

In other Atara Biotherapeutics news, insider Joe Newell sold 1,500 shares of the business’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $41.28, for a total value of $61,920.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Isaac E. Ciechanover sold 3,900 shares of the business’s stock in a transaction dated Monday, October 22nd. The shares were sold at an average price of $33.78, for a total value of $131,742.00. Following the completion of the transaction, the chief executive officer now directly owns 733,285 shares of the company’s stock, valued at $24,770,367.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,175 shares of company stock valued at $3,054,090. Insiders own 10.60% of the company’s stock.



NASDAQ:ATRA opened at $31.61 on Wednesday. Atara Biotherapeutics Inc has a 1 year low of $12.65 and a 1 year high of $54.45.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.17). As a group, equities analysts predict that Atara Biotherapeutics Inc will post -4.58 EPS for the current fiscal year.

A number of brokerages recently commented on ATRA. BidaskClub cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Friday, October 12th. Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 3rd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $45.00 price objective on shares of Atara Biotherapeutics in a research note on Friday, August 3rd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $47.80.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Read More: Marijuana Stocks

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply